Pre-made Vorsetuzumab Mafodotin benchmark antibody (Whole mAb ADC, anti-CD70/CD27-L therapeutic antibody, Anti-CD27LG/LPFS3/TNFSF7/TNLG8A Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Vorsetuzumab Mafodotin benchmark antibody (Whole mAb ADC, anti-CD70/CD27-L therapeutic antibody, Anti-CD27LG/LPFS3/TNFSF7/TNLG8A Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD7 designed for the treatment of cancer.[1] It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F (MMAF), a cytotoxic agent.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1050-1mg	1mg	4635
GMP-Bios-INN-1050-10mg	10mg	Inquiry
GMP-Bios-INN-1050-100mg	100mg	Inquiry
GMP-Bios-INN-1050-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Vorsetuzumab Mafodotin Biosimilar, Whole Mab Adc, Anti-CD70/CD27-L Antibody: Anti-CD27LG/LPFS3/TNFSF7/TNLG8A therapeutic antibody Drug Conjugate
INN Name	Vorsetuzumab Mafodotin
Target	CD70/CD27-L
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Seattle genetics, Inc. (Bothell WA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0